Drug Delivery Solutions for the Next Generation of Therapeutics

Novara™, a new advanced materials company, is poised to create a world where warmth in not just a function but a feature that elevates every product.

Replacing AFFF foam with fluorine-free alternatives can create unexpected obstacles for industrial facilities, from system incompatibilities to unclear regulations. Here's 6 of the top challenges in AFFF replacement - and how to solve them.

Battelle will host the Change Chemistry Innovators Roundtable event on September 9-11 in Columbus, OH, to convene members, partners and thought leaders for two days of collaboration, innovation and bold vision-setting.

Meet Asya Akkus, a rising senior majoring in Computer Science at Case Western Reserve University. This summer, Asya is doing more than writing code. She is engineering a software solution designed to streamline research development workflows, with the potential to standardize data management and improve efficiency across Battelle’s laboratory network.

Ever wondered what it’s really like to be an intern at Battelle? We asked Adam Helton, a third-year Ph.D. student in molecular genetics at The Ohio State University, to tell us about his experience firsthand. This summer, Adam is serving as a non-viral gene delivery intern, applying his academic expertise in a hands-on setting that’s shaping the future of gene therapy.

When Evie first walked through the doors of Battelle as a child during “Bring Your Child to Work Day,” she had no idea that years later she would return, not as a visitor, but as a valued member of the team.

The AFFF phase-out is gaining momentum across the United States, and industrial operators can't afford to ignore the shift. Here's what's driving the transition - and what it means for facilities still using Class B foams.

Gene therapy has come a long way in the last ten years. In the next decade, achieving efficiencies in its delivery will unlock its full potential.

In the European Union's stringent regulatory landscape, proactive compliance isn't just a necessity – it's a powerful strategic advantage. For plant protection product (PPP) companies, the upcoming re-registration process mandated by EU Regulation (EC) No 1107/2009, under Article 43, represents a critical juncture.

As the hospital-at-home (HaH) movement gains momentum, we’re witnessing a transformation in how and where care is delivered. Medical devices, once exclusive to hospitals are now being adapted for home use.

For meaningful and defensible PFAS testing, you need a laboratory service provider that does more than run tests—you need one that understands PFAS. Here’s what to look for when selecting a partner for PFAS laboratory analysis.

Restoring movement for people who live with paralysis has been a research imperative at Battelle since the early 2000s. Today this goal is closer than ever.

Replacing AFFF isn’t as simple as swapping one foam for another. Here's how a strategic, risk-informed approach to AFFF transition can help you make the switch with confidence.

American farmers are facing unprecedented challenges—from volatile weather patterns and rising input costs to labor shortages and global market pressures. In this environment, the crop science industry has a critical role to play in supporting the productivity of U.S. agriculture.

Over the past decade, this commitment has produced transformative training programs. These initiatives have shaped the careers of hundreds of professionals and strengthened our organization, fostering a culture of innovation, adaptability and continuous learning.

From analytical limitations to regulatory complexity, obtaining reliable, defensible PFAS data isn’t always straightforward. Here's the top challenges in PFAS analysis - and how to overcome them.

Bringing a new plant protection product (PPP) to the EU market involves navigating through a complex regulatory framework.

At Battelle, operational excellence is more than a goal- it's a shared responsibility across the U.S. Department of Energy (DOE) National Laboratories. Ed Anderson’s leadership at LANL reflects Battelle’s people-first approach to safety, trust, and mission execution.

The future of pharmaceutical manufacturing is agile. As demand for personalized therapies, rapid response, and resilient supply chains grows, the industry is shifting from traditional, rigid production to flexible, adaptive platforms. Agile manufacturing enables custom medications, on-demand therapies, and smarter, localized drug production.